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Idiopathic pulmonary fibrosis (IPF) is defined as a chronic fibrosing interstitial disease of unknown cause, limited to the
lungs, and associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP); it
generally progresses into respiratory failure and death. Although progression of the disease is the most common cause
of death, there are increasing reports of its association with other pathologies has been reported: e.g., IPF patients
seem more susceptible to cardiovascular diseases. Therefore, other pathologies might also influence the natural course.
In this paper, we describe a case of IPF and coronary artery disease (CAD). We emphasize the importance of
cardiopulmonary exercise test (CPET) as a useful procedure to monitor disease progression in IPF patients. We also
stress the importance of a careful analysis of variables measured for an accurate interpretation of the clinical picture
and an improvement of the clinical management of patients. Moreover, we suggest that a careful assessment of CPET
parameters may additionally help in the early detection of high cardiovascular ischemic risk.
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Idiopathic pulmonary fibrosis (IPF) is defined as a form of
chronic, progressive fibrosing interstitial pneumonia of
unknown cause, occurring primarily in older adults, limited
to the lungs, and associated with histopathologic and/or
radiologic pattern of usual interstitial pneumonia (UIP) [1].
People with IPF usually die because of progression of their
underlying lung disease [2], even if there is evidence of
increased incidence of other diseases, such as lung cancer
[3,4], which could affect the time of death. Furthermore,
IPF patients seem more susceptible to developing coronary
artery disease (CAD) than people with non fibrotic lung
disease or other non-IPF pulmonary fibrosis [5]. Cardio-
pulmonary exercise test (CPET) is widely employed in
patients with heart/lung diseases to study the level of
exercise tolerance and to define either preoperative risk for
thoracic surgery, or the response to pharmacological ther-
apy and to rehabilitation programmes. For this purpose
a cluster of parameters are used [6,7]: work efficiency
(WR, work rate), metabolic response (VO2, oxygen uptake;* Correspondence: fpolverino@partners.org
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unless otherwise stated.VCO2, carbon dioxide output; AT, anaerobic threshold),
ventilatory/respiratory response (TV, tidal volume; Rf,
respiratory frequency; VE, minute ventilation;VE/VCO2
and VE/VO2 ratios, ventilatory equivalents; VD/VT, ratio of
physiologic dead space to tidal volume), and cardiovascular
response (HR, heart rate; VO2/HR, oxygen-pulse; ΔVO2/
ΔWR, change in the oxygen uptake related to the increase
in work rate), PaO2, PaCO2, pulmonary gas exchange
(arterial oxygen and carbon dioxide partial pressures;
SaHbO2, arterial O2 saturation). CPET is rarely of diag-
nostic use in patients with respiratory or cardiovascular
dissease. However, it can aid in the clinical management of
patients with established cardiopulmonary diseases.
In this paper we describe a case of IPF and CAD,
emphasizing the role of CPET in early diagnosis of CAD.Case presentation
A 60-yr old Caucasian man was admitted to the hospital
due to a dry cough and progressive dyspnoea on exertion.
The patient reported a history of smoking, but no systemic
disease, or occupational exposure, and was not taking any
medications. Physical examination revealed bilateral basal
inspiratory crackles. A High Resolution Computed Tomo-
graphy (HRCT) scan showed basal distribution of reticularal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Oxygen pulse (VO2/HR) at the time of the diagnosis.
x-axis: VO2; left y-axis: heart rate (HR) represented by red dots; right y-axis:
VO2/HR represented by blue dots.
Figure 2 Oxygen pulse (VO2/HR) after cardiac therapy. x-axis:
VO2; left y-axis: heart rate (HR) represented by red dots; right y-axis:
VO2/HR represented by blue dots.
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combing. Pulmonary function tests (PFT) were abnormal
as spirometry indicated restriction (TLC 76%, FVC 97%,
FEV1 102%, FEV1/VC 76.9%), reduced diffusing capacity for
carbon monoxide (DLCO 77.5%), with a preserved ratio of
DLCO/VA (111%). Bronchoalveolar lavage (BAL) sampling
revealed a mild granulocytic alveolitis (88% macrophages,
5% lymphocytes, 5% neutrophils and 2% eosinophils) and
reduced lymphocytic subpopulation ratios (CD4/CD8 0.5).
Arterial blood gases were normal under resting conditions
(pH 7.38; PaO2 90 mmHg; PaCO2 42 mmHg; SaO2 97%),
but not during exercise, when mild hypoxemia was seen
(PaO2 60 mmHg). Neither an echocardiographic examin-
ation nor a CPET showed pathological signs. Instead,
normal work efficiency, metabolic, ventilatory, and cardio-
vascular responses were obtained; in particular, a linear
increase in VO2, together with an increase in work rate
above the anaerobic threshold, was found. Due to diagnos-
tic uncertainty, three months after the previous assessment
the patient underwent a complete functional reassessment
including a renewed CPET, which did not show any rele-
vant changes. The patient was then subjected to a thoraco-
scopic lung biopsy (Video-Assisted Thoracoscopic Surgery,
VATS) which revealed a pattern of UIP, thus confirming
the IPF diagnosis. In order to monitor the course of the
illness, the patient was closely monitored with additional
clinical and physiologic testing. In this context, two months
after performing a surgical lung biopsy, the patient repeated
PFTs and an echocardiographic study. However, these
investigations did not show significant changes from the
previous two evaluations, except for a mild reduction in
resting oxygenation (PaO2 70 mm Hg). However, analysis
of CPET, in spite of normal metabolic and ventilatory re-
sponses, showed an abnormal cardiovascular finding rela-
tive to the pattern of increased increase of increase VO2
relative to work rate below and above anaerobic threshold
(Figure 1A): the ΔVO2/ΔWR ratio was reduced from
11.3 ml/min/W to 6.9 ml/min/; furthermore, changes both
in oxygen-pulse (Figure 1B) and in electrocardiographic
signs that could be due to different causes were observed.
The patient was referred to a Cardiology Unit, where a
diagnosis of acute coronary syndrome (ACS) was made and
percutaneous transluminal coronary angioplasty (PTCA)
was performed.
Six months after the patient’s referral to the Cardiology
Unit, another CPET showed a totally normal result both
with respect to the ΔVO2/ΔWR ratio and the oxygen-pulse
(Figure 2).
Discussion
CPET is a well accepted technique utilized in clinical
practice to evaluate cardiovascular and respiratory inter-
actions during physical exercise. It is not routinely used in
the management of IPF patients but, when performed,some parameters may have prognostic significance [8,9].
In addition, although IPF, by definition, is a progressive
chronic fibrosing disease limited to the lung, the heart
might be involved when gas exchange is so altered that
coronary flow is affected. In this context, CPET could be a
useful tool to investigate subclinical CAD [10]. While the
progression of the underlying lung disease is the most com-
mon cause of death for patients with IPF [2], various stud-
ies seem to suggest an additional increase in cardiovascular
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impact on morbidity and mortality. In spite of this, IPF
guidelines do not recommend routine screening to evaluate
the presence of cardiovascular complications, as it is not
clear whether treating comorbidities may influence survival
[1]. However, in the context of comprehensive care of IPF
patients, an holistic approach was recently proposed [12],
in which identifying and treating comorbidities, such as
CAD, could be a strategy to optimize the management of
the disease. In the cardiological context, CPET is a well
recognized method to diagnose and/or investigate cardio-
vascular dysfunction (e.g., myocardial ischemia, chronic
heart failure) [10,13]. With respect to lung diseases, the goal
of CPET is the identification of physiopathological determi-
nants of respiratory dysfunction as well as matching the
pattern of the abnormality with the particular sites of the
system involved, thus clarifying the clinical picture and
possibly narrowing the differential diagnosis [14,15]. Fur-
thermore, the physiological link between respiratory and
cardiovascular functions might cause the changes in one
system to influence the performance of the other. That is,
deterioration in gas exchange could be the cause of CAD,
which could manifest as changes in the slope of ΔVO2/
ΔWR and a flattening of the oxygen-pulse [16]. In previous
studies, various indices of exercise capacity have been
evaluated as prognostic factors for IPF [9,17], in particular
VO2-max [18]. Moreover, they were shown to be signifi-
cantly related to prognosis when baseline values and
percent variation over time were assessed. Although the
results of these investigations were not concordant [19],
due at least partially to the employment of different meth-
odologies, gas exchange impairment during exercise has
generally been emphasized as a factor influencing clinical
progression of disease in IPF patients.
In our clinical practice, we perform PFTs on IPF patients
to monitor progression of the pulmonary disease and to
obtain data facilitating its management, such as the optimal
time for referral of the patients to a lung transplantation
center. Whenever possible, we use CPET to detect early
changes in pulmonary physiology, especially gas exchange,
and to verify the presence of cardiovascular abnormalities.
We hereby confirm the importance of CPET as a useful
procedure to monitor disease progression in IPF patients.
CPET can be useful in differentiating whether the worsen-
ing of dyspnoea leading to exercise limitation is related to
pulmonary or cardiovascular causes. Discriminating be-
tween these two possible causes of dyspnoea worsening can
be useful in the decision-making process during the
management of the patient (e.g., for inclusion in clinical
trials and transplantation referral). Furthermore, we stress
the necessity of a careful analysis of variables measured for
an accurate interpretation of the clinical picture. In particu-
lar, we consider that an in-depth study should be started
even when slight and/or uncertain responses are obtainedfrom the analysis of involved variables, and even if uncer-
tainties occur in only one of several relevant parameters. In
the case described herein, we requested a cardiac workup
soon after the time of the initial diagnostic suspicion of
CAD. This resulted in an earlier clinical diagnosis and
earlier initiation of treatment of the patient.Conclusions
The conclusion that might be drawn from this report is that
a more extensive CPET should be performed for better
management of IPF patients, not only with the goal of
identifying useful prognostic parameters, but also to detect
potentially treatable cardiovascular alterations earlier.
The careful assessment of CPET parameters (e.g., O2
pulse and work efficiency above and below the anaerobic
threshold) may not only improve clinical management of
IPF patients, but also identify factors predisposing to
higher ischemic risk. However, further studies are needed
to assess the costs and benefits of associated with general-
ized use of CPET in the care of IPF patients.
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